Theravance has begun a Phase II study with TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor (NSRI), for the treatment of fibromyalgia.

TD-9855, the lead compound in Theravance’s monoamine reuptake inhibitor programme, was discovered for the treatment of central nervous system (CNS) conditions such as chronic pain and Attention Deficit Hyperactivity Disorder (ADHD).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

"The Phase II proof-of-concept study will randomise around 375 fibromyalgia patients with TD-9855 or placebo, once-daily for up to nine weeks, and assess the safety and efficacy of two TD-9855 doses."

Theravance research and early clinical development senior vice president Dr Mathai Mammen said there is considerable opportunity for therapies with a reasonable tolerability profile that manage both fibromyalgia and commonly experienced comorbid symptoms.

"We believe TD-9855’s balance of inhibition of norepinephrine and serotonin reuptake may provide a compelling and differentiated profile versus current alternatives," Mammen said.

The Phase II proof-of-concept study will randomise around 375 fibromyalgia patients with TD-9855 or placebo, once-daily for up to nine weeks, and assess the safety and efficacy of two TD-9855 doses.

See Also:

Improvement in pain is the primary endpoint of the study, while additional secondary or exploratory endpoints include improvement in other established fibromyalgia measures and impact on important comorbidities, such as fatigue.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Besides the Phase II fibromyalgia study, the company is evaluating TD-9855 in an ongoing Phase II safety and efficacy study in adults with ADHD.

The monoamine reuptake inhibitor programme is focused on developing a monoamine reuptake inhibitor for the treatment of diverse CNS conditions such as chronic pain, ADHD and potentially depressive disorders.